New immunotherapy studies for people with advanced melanoma

July 24, 2017

Two new studies of investigational and FDA-approved immunotherapies for advanced melanoma are opening soon at Providence Cancer Institute.

Opening in July: A phase 3, randomized study of adjuvant immunotherapy with nivolumab combined with ipilimumab versus ipilimumab or nivolumab monotherapy after complete resection of stage IIIb/c/d or stage IV melanoma

Purpose: To determine whether an investigational immunotherapy, nivolumab, when combined with ipilimumab, is more effective than nivolumab or ipilimumab by itself, in delaying the return of cancer in patients who have had a complete surgical removal of stage IIIb/c/d or stage IV melanoma.

Opening in August: A phase II randomized, open-label, multi-center study of the safety and efficacy of IMCgp100 compared with Investigator Choice in HLA-A*0201-positive patients with previously untreated advanced uveal melanoma

Purpose: To evaluate the overall survival of HLA-A*0201-positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab or pembrolizumab.

For more information or to refer patients to these new studies, please call Providence Cancer Institute’s Clinical Trials office at 503-215-2614. In addition, 10 more melanoma studies are open and ongoing at Providence Cancer Institute.

See all open melanoma studies ›

See all Providence studies in all cancer types ›

Leaders in melanoma research and treatment

Providence Cancer Institute has been an international leader in melanoma research and treatment for more than 20 years. Some highlights of our program and contributions:

  • Providence Cancer Institute researchers led the international study leading to FDA approval of ipilimumab (Yervoy), the first immunotherapy to show a survival benefit in advanced melanoma.
  • Providence also participated in clinical trials leading to FDA approval of the PD-1/PD-L1-blocking antibodies pembrolizumab and nivolumab (Keytruda and Opdivo), which offer improved response and survival benefits as second- or third-line therapies for patients with metastatic melanoma.
  • Providence is one of the top five high-dose Interleukin-2 centers in the country and is an innovator in the use of IL-2 in conjunction with high-dose per fraction radiation.
  • Providence is one of the few melanoma centers offering tumor infiltrating lymphocyte (TIL) therapy in combination with IL-2.

Learn more about the Providence Cancer Institute Melanoma Program.